To determine the distribution of CAR-T cells after administration, we conducted in vivo assays using NCG mice with or without tumor cells, and launched a small-scale clinical trial to study the pharmacokinetics of CD19 CAR-T cells in the blood of 13 B-NHL patients. The gene discussed is CD19; the disease is neoplasm.